



# 2curex

- because cancer patients are individuals

## Application of IndiTreat<sup>®</sup>

Henrik Harling, MD DMSci  
2cureX Chief Medical Officer



## Current chemotherapy of metastatic colorectal cancer


FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Christophe Tournigand<sup>1</sup>, Thierry André, Emmanuel Achille, Gérard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gérard Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, Aimery de Gramont


J Clin Oncol 2004;22: 229-37

# Resistance to treatment with FOLFOX and FOLFIRI

---



1<sup>st</sup> line treatment



2<sup>nd</sup> line treatment

*What if we could better predict response rate in chemo-naïve patients?*


# IndiTreat® the world's first IVD CE validated cancer sensitivity test

---

A cancer sensitivity test based on patient derived microtumors which match a patient to a drug by directly testing their live tumor tissue.

**Ineffective medical treatment**

**Effective medical treatment selected by IndiTreat®**




- because cancer patients are individuals

# Functional microtumor response (IndiTreat<sup>®</sup>) to 1L regimens in colorectal cancer

2cureX's Reference Data Bank

Patient	5-FU	FOLFIRI	FOLFIRI + Cetuximab	FOLFOX	FOLFOX + Cetuximab	Oxaliplatin	SN38
Pt672	Red	Green	Light Green	Light Green	Red	Light Green	Orange
Pt676	Red	Light Green	Orange	Green	Orange	Light Green	Red
Pt669	Red	Light Green	Red	Orange	Red	Light Green	Light Green
Pt667	Orange	Green	Light Green	Green	Green	Green	Red
Pt670	Orange	Red	Light Green	Red	Red	Red	Red
Pt662	Red	Orange	Light Green	Light Green	Red	Orange	Red
Pt659	Red	Light Green	Red	Light Green	Orange	Orange	Red
Pt640	Green	Green	Green	Green	Green	Green	Light Green
Pt645	Light Green	Green	Light Green	Red	Light Green	Light Green	Red
Pt646	Green	Green	Orange	Green	Light Green	Green	Red
Pt663	Orange	Light Green	Light Green	Orange	Light Green	Red	Red
Pt648	Orange	Light Green	Light Green	Red	Red	Red	Red
Pt630	Red	Red	Red	Red	Light Green	Red	Red
Pt640	Green	Green	Green	Green	Green	Red	Light Green
Pt676	Red	Light Green	Green	Red	Red	Red	Orange
Pt627	Light Green	Green	Green	Green	Light Green	Red	Light Green
Pt738	Orange	Green	Green	Orange	Light Green	Orange	Green
Pt733	Light Green	Light Green	Light Green	Light Green	Light Green	Red	Red
Pt727	Red	Orange	Red	Red	Red	Red	Red
Pt716	Red	Red	Red	Red	Red	Red	Red
Pt711	Light Green	Green	Green	Light Green	Green	Red	Light Green
Pt708	Light Green	Green	Green	Light Green	Green	Light Green	Light Green
Pt846	Light Green	Orange	Light Green	Light Green	Light Green	Orange	Light Green
Pt806	Green	Green	Green	Green	Green	Red	Light Green
Pt765	Orange	Green	Light Green	Orange	Orange	Red	Red
Pt637	Light Green	Light Green	Green	Light Green	Light Green	Red	Light Green



- because cancer patients are individuals

# IndiTreat testing in third-line metastatic colorectal cancer

## 2cureX's Reference Data Bank

Patient




5FU	FolFiri	FolFiri + Cetuximab	FolFox	FolFox + Cetuximab	Oxaliplatin	Irinotecan	Vinorelbine	Tas-102	Sorafenib	Regorafenib	Olaparib	Epirubicin
Red	Red	Red	Red	Red	Yellow	Red	Red	Green	Red	Red	Yellow	Red

Effective Treatment



Stage IV patients

### Sensitivity



- because cancer patients are individuals

# The power of functional and genomic precision

NGS

IndiTreat supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity

IndiTreat®

- because cancer patients are individuals

# 2cureX

**The power of precision.  
For every Oncologist.  
Today.**

- because cancer patients are individuals